NLS Pharmaceutics AG (NLSP) Stock

About NLS Pharmaceutics AG

NLS Pharmaceutics AG is a biopharmaceutical firm dedicated to researching and creating treatments for intricate and uncommon conditions affecting the central nervous system. Its primary focus includes advancing medications for narcolepsy, idiopathic hypersomnia, and various other unusual sleep conditions, alongside neurodevelopmental challenges like attention deficit hyperactivity disorder (ADHD). Key experimental compounds in its pipeline are Quilience, designed to address excessive daytime sleepiness and cataplexy, and Nolazol, which targets ADHD. Established in 2015, the company maintains its headquarters in Zurich, Switzerland.

NLS Pharmaceutics AG is headquartered in CH.

NLS Pharmaceutics AG (NLSP) stock trades at $2.91 with a market capitalization of $919601. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.43, reflecting a net loss over the last twelve months, price-to-book of 1.86, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.76 and $43.40, and currently trades 93.3% below its 52-week high.

On profitability, NLS Pharmaceutics AG generates a return on equity (ROE) of 41.94%, above the typical market range of roughly 12-15%, return on capital employed of -81.09%.

Official website: nlspharma.com